G. Perugi, C. Torti, M.C. Travierso - Vol. 8, September 2002, Issue 3
Testo Immagini Bibliografia Summary Indice
Gli antipsicotici atipici nei disturbi dell’umore
Atypical antipsychotics in mood disorders
2 Keck PE Jr, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balistreri TM, et al. Factors associated with maintenance antipsycotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996;57:147-51.
3 Sachs Gs. Use of clonazepam for bipolar affective disorder. J Clin Psychiatry 1990;51:31-4.
4 Verdoux H, Gonzales B, Takei N, Bourgeois M. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. J Affect Disord 1996;38:81-7.
5 Zarate CA Jr, Tohen M. Antipsycotic drug treatment in first-episode mania:a 6-month longitudinal study. J Clin Psychiatry 2000a;61:33-8.
6 Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine:relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
7 Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia:a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-9.
8 Daskalakis Z, Christensen B, Zipursky R, Zhang-Wong J, Beiser M. Relationship between D2 occupancy and prolactin levels in first episode psychosis. Biol Psychiatry 1998;43:113S.
9 Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia:a PET investigation. Am J Psychiatry 1998a;155:921-8.
10 Knable MB, Heinz A, Raedler T, Weinberger DR. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatr Res Neuroimaging 1997;75:91-101.
11 Scherer J, Tatsch K, Schwarz J, Oertel W, Kirsch MC, Albus M. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psychiatry 1994;36:627-9.
12 Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, et al. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) 1999;141:175-81.
13 Jones C, Kapur S, Remington G, Zipursky RB. Transient dopamine D2 occupancy in low EPS-incidence drugs: PET evidence. Biol Psychiatry 2000;47(8 suppl):112.
14 Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
15 Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain:a PET study with risperidone. Psychopharmacology (Berl) 1993;110:265-72.
16 Nyberg S, Farde L, Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997;16:1-7.
17 Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors:implications for the treatment of schizophrenia. Am J Psychiatry 1997;154:1525-9.
18 Martinot JL, Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry. 1998;155:505-8.
19 Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-70.
20 Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR. Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci 1997;18:186-8.
21 Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsycotics? A new hypothesis. Am J Psychiatry 2001;158:360-9.
22 Burki HR. Effects of fluperlapine on dopaminergic systems in rat brain. Psychopharmacology (Berl) 1986;89:77-84.
23 Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori T, Meltzer HY. Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. J Neural Transm 1987;68:227-40.
24 Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:285-92.
25 Flaum M, Andreasen NC. The reliability of distinguishing primary versus secondary negative symptoms. Compr Psychiatry 1995;36:421-7.
26 Hippius H. The history of clozapine. Psychopharmacolgy 1989;99:S3-S5.
27 Stevens JR, Denney D, Szot P. Sensitization with clozapine:beyond the dopamine hypothesis. Biol Psychiatry 1997;42:771-80.
28 Kane J, Honigfeld G, Singer J, Meltzer H. Clozaril Collaborative Group. Clozapine for treatment resistant schizophrenia. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
29 Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-54.
30 McElroy SL, Dessain EC, Pope HG, Cole JO. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorders and schizophrenia. J Clin Psychiatry 1991;52:411-4.
31 Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M, et al. Clozapine in refractory affective disorders:polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300.
32 Calabrese JR, Kimmel SE, Woyshville MJ, Rappaport DJ, Faust CJ, Thompson PA, et al. Clozapine for treatment refractory mania. Am J Psychiatry 1996;153:759-64.
33 Battegay R, Cotar B, Fleishenhauer J, Rauchfleish U. Results and side effects of treatment with clozapine. Comp Psychiatry 1977;18:423-42.
34 Suppes T, Mc Elroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-80.
35 Zarate CA Jr, Thoen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995a;56:411-7.
36 Leppig M, Bosch B, Naber D, Hippius H. Clinical managment of clozapine patients in relation to efficacy and side-effects. Brit J Psychiatry 1989;160:54-9.
37 Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995b;56:108-12.
38 Suppes T, Rush AJ, Webb A, Carmody T, Kraemer H. One year randomized trial clozapine vs. ususal care in bipolar I patients. Biol Psychiatry 1996;39:531.
39 Kando JC, Tohen M,Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994;55:255-7.
40 Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, et al. Serum concentrations of clozapine and its major metabolites:effects of co-treatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5.
41 Longo LP., Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am J Psychiatry 1995;152:650 (letter).
42 Costello L, Suppes T. A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 1995;15:139-40.
43 Wilson W. Do anticonvulsivant hinder clozapine treatment? Biol psychiatry 1995;37:132-3.
44 Graham SR, Kokkinidis L. Clozapine inhibits limbic system kindling:implications for antipsychotic action. Brain Res Bull 1993;30:597-605.
45 Junghan U., Albers M., Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry 1993;26:262 (letter).
46 Tiihonen J., Vartianen H., Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28:26-8 (letter).
47 Raitasuo V, Lehtovaara R., Huttunen MO. Carbamazepine and plasma levels of clozapine. Am J Psychiatry 1993;150:169 (letter).
48 Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988;2:1500 (letter).
49 Backer R, Ames D, Umbricht D, Chengappa KNR, Schooler NR. Olanzapine’s impact on depressive and obsessive-compulsive symptoms in schizophrenia. Psychopharmacol Bull 1995;31:549.
50 Tollefson GD, Beasley CM, Tran PV, Steet JS. Olanzapine vs. Haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders:results of an international collaboration. AM J Psychiatry 1997;154:457-65.
51 Thoen M, Sanger T, Tollefson GD, McElroy SL. Olanzapine vs. Haloperidol in the treatment of schizoaffective bipolar patients. 1997 Annual Meeting of American Psychiatric Association, May 17-22 San Diego, California.
52 Mc Elroy SL, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R, et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998;49:119-22.
53 Sharma V, Pistor L. Treatment of bipolar mixed states with olanzapine. J Psychiatr Neurosci 1999;24:40-4.
54 Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry 1999;60:116-8.
55 Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania:a double blind randomized controlled trial. Int Clin Psychopharmacol 1999;14:339-43.
56 Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;156:702-9.
57 Gonzalez-Pinto A, Lalaguna B, Mosquera F, Perez de Heredia JL, Gutierrez M, et al. Use of olanzapine in dysphoric mania. J Affect Disord 2001;66:247-53.
58 McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis and antipsychotics. 1996;57:14-26.
59 Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001;11:239-50.
60 Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97.
61 Vieta E, Herraiz M, Fernandez A, Gasto C, Benabarre A, Colom F, et al. Efficacy and safety of risperidone in the treatment of schizoaffective disorder:initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). J Clin Psychiatry 2001;62:623-30.
62 Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273-81.
63 Zarate CA Jr, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S, et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998;59:24-8.
64 Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H. Risperidone vs. clozapine in the treatment of schizophrenic patients with acute symptoms:a double blinde, randomized, trial. Prog Neuropsychopharmacol 1994;18:127-37.
65 Dwight MM, Keck PE Jr, Stanton SP, Strakowski SM, Mc Elroy SL. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994;344:554-5 (letter).
66 O’Cronin ZT & Holt L. Hypomania associated with risperidone. Can J Psychiatry 1995;2:51.
67 Koek RJ & Kessler CC. Probable induction of mania by risperidone. J Clin Psychiatry 1996;57:174-5.
68 Diaz SF. Mania associated with risperidone. J Clin Psychiatry 1996;57:41-2.
69 Roose K, Gelders Y, Heylen S. Risperidone in psychotic patients:a first clinical therapeutic experience. Acta Psychiatr Belg 1988;88:233-41.
70 Singh AN, Catalan J. Risperidone in HIV-related main psychosis. Lancet 1994;344:1029-30.
71 Goodnick PJ. Risperidone treatment of refractory acute mania. J Clin Psychiatry 1995;56:431-2.
72 Thoen M, Zarate CA Jr, Centorrino F. Risperidone in the treatment of mania. J Clin Psychiatry 1996;57:249-53.
73 Ghaemi SN, Sachs GS, Baldassano C, Truman C. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry 1997;42:196-9.
74 Shaffer CG & Shaffer LC. The use of risperidone in the treatment of bipolar disorder. J Clin Psychiatry 1996;57:136.
75 Sajatovic M, Di Giovanni SK, Bastani B, Hattab H, Ramirez LF. Risperidone therapy in treatment refractory, acute bipolar and schizoaffective mania. Psychopharmacol Bull 1996;32:55-61.
76 Tomlison CW. Risperidone and mania. Am J Psychiatry 1996;153:132-3.
77 Barkin JS & Pais VM. Induction of mania by risperidone resistant to mood stabilizer. J Clin Psychopharmacol 1997;17:56-7.
78 Hillert A, Maier W, Wetzel H, Benkert O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - a functional approach. Pharmachopsychiatry 1992;25:213-7.
79 Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F, et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001;21:469-73.
80 Janicak PG, Keck PE Jr, Davis JM, Kasckow JW, Tugrul K, Dowd SM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 2001;21:360-8.
81 Keck PE Jr, Wilson DR. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorder. J Clin Psychiatry 1995;56:466-71.
82 Ghaemi SN, Katzov JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999;11:137-40.
83 Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000b;61:185-9.
84 Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly partients with psychotic disorders. J Geriatr Psychiatry Neurol 2000;13:28-32.
85 Sajatovic M, Brescan DW, Perez DE, DiGiovanni SK, Hattab H, Ray JB, et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001;62:728-32.
86 Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;778-83.
87 Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-9.
88 Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-43.
89 Alvir JMJ, Lieberman JA, Safferman AZ, Schvimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. N Engl J Med 1993;329:162-7.
90 Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, Dqw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47:945-8.
91 Barnas C, Zwierzina H, Hummer M, Sperner-Unterweger B, Stern A, Fleischhacker WW. Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis:a case report. J Clin Psychiatry 1992;55:44-9.
92 Lambert JS, Bellnier TJ, Schwarzkopf SB. Filgrastim treatment of three patients with clozapine-induced Psychiatry agranulocytosis. J Clin Psychiatry 1995;56:256-9.
93 Lieberman JA, Safferman Az. Clinical profile of clozapine:adverse reactions and agranulocytosis. Psichiatr Q 1992;63:51-70.
94 Toth P, Frankenburg Fr. Clozapine and seizures:a review. Can J Psychiatry 1994;39:236-8.
95 Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo:results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-67.
96 Beasley CM Jr, Hamilton Sh, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol:acuse phase results of international double-blind olanzapina trial. Eur Neuropsychopharmacol 1997;7:125-37.
97 Conley RR, Mahmoud R, and the Risperidone Study Group. Risperidone vs olanzapine in patiens with schizophrenia and schizoaffective disorder. Presended at the annual meeting of the American College of Neuropsychopharmacology, Dec 12-16, 1999, Acapulco, Mexico.
98 Conley RR, Tamminga CA, Bartko JJ, Richardson E, Peske M, Linge J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-20.
99 Sachs GS, Guille C, Demopulos C. Atipical antipsycotics:use in bipolar disorder clinic. Presented at the 21st Collegium Internationale Neuropsychopharmacologicum Conference, July 11, 1998, Glasgow, UK.
100 Sheitman BB, Bird PM, Binz W. Olanzapine-induced elevation of plasma triglyceride. Am J Psychiatry 1999;156:1471-2 (letter).
101 Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001;21:369-74.
102 Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 2001;138:936-8.
103 Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001;35:563-5.
104 Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medication:new case report and review of the literature. J Am Board Fam Pract 2001;14:278-82.
105 Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-9.
106 Mir S, Taylor TD. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16:63-73.
107 Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Psychopharmacol 1993;13:25-40.
108 Peuskens J, on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia:a multi-national, multicentre, double blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
109 Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
110 Guitierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general use. Int Clin Psychopharmacol 1997;12(suppl 4):S3-S10.
111 Allison DB, Mentor JL, Heo M. Weight gain associated with conventional and newer antipsychotics:a meta-analysis. In:New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association, June 3, 1998, Toronto Canada. Abstract NR 497:202.
112 Daniel DG, Golberg TE, Weinberger DR. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-9.
113 Seroquel (quetiapine). Physicians’Desk Reference. Montale, NJ: Medical Economics, 1999.
114 American Psychiatric Aassociation. Practice guideline for the treatment of patients with Bipolar Disorder (Revision);Supplement to the Am J Psychiatry 2002;159:1-50.